<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04353778</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 18-2812</org_study_id>
    <secondary_id>1R01DK122853-01A1</secondary_id>
    <nct_id>NCT04353778</nct_id>
  </id_info>
  <brief_title>Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV</brief_title>
  <acronym>EVA</acronym>
  <official_title>Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study team's prior research has shown that dysfunction of a specific nerve, called the&#xD;
      vagus nerve, is associated with small intestinal bacterial overgrowth (SIBO), and that SIBO&#xD;
      is associated with signs of inflammation in the blood of people living with HIV (PLWH). This&#xD;
      research will explore pathways linking vagal dysfunction to inflammation in HIV, focusing on&#xD;
      the gastrointestinal tract, and study whether a medication called pyridostigmine and&#xD;
      stimulation of the vagus nerve are beneficial therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives Aim 1: To elucidate mechanisms linking VD, SIBO and chronic inflammation in PLWH.&#xD;
      PLWH (N=150) will undergo autonomic function tests (AFTs) for VD, hydrogen/methane breath&#xD;
      testing (HBT) for SIBO, Wireless Motility Capsule (WMC, SmartPill) testing for GI transit&#xD;
      times and pH measurements, blood draw for quantification of inflammatory mediators, and&#xD;
      collection of stool samples and oral swabs for characterization of the GI microbiome.&#xD;
&#xD;
      Hypothesis 1a (primary): The relationship between VD and SIBO in HIV is mediated by prolonged&#xD;
      small bowel transit time (SBTT) and hypochlorhydria.&#xD;
&#xD;
      Hypothesis 1b (exploratory): There is an additional pathway linking VD and elevated IL-6 in&#xD;
      PLWH which is independent of SIBO and bacterial translocation.&#xD;
&#xD;
      Aim 2: To determine whether the relationship between VD and SIBO is modified by the presence&#xD;
      of HIV-infection. HIV-infection results in disruption of the GI mucosal barrier,5 which could&#xD;
      make PLWH more vulnerable to adverse GI effects of VD. HIV-uninfected controls (N=100), age&#xD;
      and gender matched to the PLWH from Aim 1, will undergo the same assessment as the PLWH. The&#xD;
      study team will test for effect modification of the VD-SIBO relationship by HIV status, using&#xD;
      logistic regression to examine the interaction between VD and HIV.&#xD;
&#xD;
      Aim 3: To establish vagal pathways as a viable treatment target for individuals with&#xD;
      well-controlled HIV. PLWH with VD, SIBO and/or prolonged SBTT (N=96) will be identified from&#xD;
      the Aim 1 cohort. The first 86 eligible patients will be randomized to 8 weeks of&#xD;
      pyridostigmine versus placebo; the remaining 10 will receive 8 weeks of open-label&#xD;
      noninvasive vagal nerve stimulation (nVNS) to assess feasibility. All patients will then be&#xD;
      retested (AFTs, HBT, SmartPill, blood draw, stool samples and oral swabs).&#xD;
&#xD;
      Hypothesis 3a (primary): Eight weeks of low-dose pyridostigmine (30mg PO TID) will reduce&#xD;
      SIBO as compared to placebo in PLWH. Hypothesis 3b (exploratory): Non-invasive VNS is safe,&#xD;
      well tolerated and acceptable to PLWH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Small bowel transit time (SBTT)</measure>
    <time_frame>5 years</time_frame>
    <description>Small bowel transit time (SBTT) measured by wireless motility capsule (wmc, smartpill)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastric pH measurement</measure>
    <time_frame>5 years</time_frame>
    <description>Gastric pH measurement measured by wireless motility capsule (wmc, smartpill)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hydrogen/methane breath testing (hbt)</measure>
    <time_frame>5 years</time_frame>
    <description>hydrogen/methane breath testing (hbt) to measure small intestinal bacterial overgrowth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL6 measurement. [Time Frame: 5 years]</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>HIV</condition>
  <condition>Non-HIV</condition>
  <condition>Vagus Nerve Dysfunction</condition>
  <arm_group>
    <arm_group_label>PLWH</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>People living with HIV (HIV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy controls who do not have HIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pyridostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PLWH on pyridostigmine 30mg PO TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLWH on placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nVNS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PLWH to undergo non-invasive vagal nerve stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridostigmine</intervention_name>
    <description>Eight weeks of low-dose pyridostigmine</description>
    <arm_group_label>Pyridostigmine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>matching placebo x 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>non-invasive vagal nerve stimulation</intervention_name>
    <description>stimulation of the vagus nerve</description>
    <arm_group_label>nVNS</arm_group_label>
    <other_name>nVNS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  Greater than or equal to18 years old (18 to 64 Years, 65 Years and Over)&#xD;
&#xD;
          -  Documentation of HIV-1 infection&#xD;
&#xD;
          -  Stable CART for greater or equal to 3 months&#xD;
&#xD;
          -  HIV-1 viral load &lt;100 copies/ml (within 3m)&#xD;
&#xD;
          -  No diagnosis known to cause autonomic or GI dysfunction other than HIV (e.g.&#xD;
             Parkinson's disease, diabetes, peptic ulcer disease, infectious diarrhea)&#xD;
&#xD;
          -  Willing to refrain from nicotine use for 24h prior to all testing&#xD;
&#xD;
          -  No contraindication to autonomic testing (e.g. uncontrolled glaucoma, heart rate not&#xD;
             under sinus control)&#xD;
&#xD;
          -  No medications with significant autonomic or GI effects (e.g. sympathomimetics,&#xD;
             prokinetics, anti-diarrheals, antibiotics)&#xD;
&#xD;
          -  Urine test negative for stimulants and opiates/opioids and pregnancy test (if&#xD;
             applicable)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dysphagia to food or pills&#xD;
&#xD;
          -  Known or suspected obstructive disease of the GI tract (e.g. bezoar, strictures,&#xD;
             fistulae, physiologic GI obstruction)&#xD;
&#xD;
          -  GI surgery within 3m, Crohn's disease, diverticulitis, any electromechanical medical&#xD;
             device (e.g. pacemaker, infusion pump).&#xD;
&#xD;
          -  Contraindication to pyridostigmine (e.g. mechanical intestinal or urinary obstruction,&#xD;
             hypersensitivity to pyridostigmine, cardiac arrhythmias, asthma, chronic obstructive&#xD;
             pulmonary disease); use of pyridostigmine within the past 6m.&#xD;
&#xD;
          -  History of intracranial aneurysm/hemorrhage, brain tumor, abnormal neck anatomy, or&#xD;
             implants or metal hardware near site of stimulation; exposure to VNS within the past&#xD;
             6m.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Robinson-Papp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Nmashie, MD</last_name>
    <phone>212-241-3193</phone>
    <email>Alexandra.nmashie@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary Catherine George, MM, PhD</last_name>
    <phone>212-241-0784</phone>
    <email>mary-catherine.george@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Nmashie, MD</last_name>
      <phone>212-241-3193</phone>
      <email>Alexandra.nmashie@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Catherine George, MM,PhD</last_name>
      <phone>212-241-0784</phone>
      <email>mary-catherine.george@mssm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jessica Robinson- Papp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Robinson-Papp J, Nmashie A, Pedowitz E, George MC, Sharma S, Murray J, Benn EKT, Lawrence SA, Machac J, Heiba S, Kim-Schulze S, Navis A, Roland BC, Morgello S. The effect of pyridostigmine on small intestinal bacterial overgrowth (SIBO) and plasma inflammatory biomarkers in HIV-associated autonomic neuropathies. J Neurovirol. 2019 Aug;25(4):551-559. doi: 10.1007/s13365-019-00756-9. Epub 2019 May 16.</citation>
    <PMID>31098925</PMID>
  </reference>
  <reference>
    <citation>Carod-Artal FJ. Infectious diseases causing autonomic dysfunction. Clin Auton Res. 2018 Feb;28(1):67-81. doi: 10.1007/s10286-017-0452-4. Epub 2017 Jul 20. Review.</citation>
    <PMID>28730326</PMID>
  </reference>
  <reference>
    <citation>Robinson-Papp J, Nmashie A, Pedowitz E, Benn EKT, George MC, Sharma S, Murray J, Machac J, Heiba S, Mehandru S, Kim-Schulze S, Navis A, Elicer I, Morgello S. Vagal dysfunction and small intestinal bacterial overgrowth: novel pathways to chronic inflammation in HIV. AIDS. 2018 Jun 1;32(9):1147-1156. doi: 10.1097/QAD.0000000000001802.</citation>
    <PMID>29596112</PMID>
  </reference>
  <reference>
    <citation>Paulon E, Nastou D, Jaboli F, Marin J, Liebler E, Epstein O. Proof of concept: short-term non-invasive cervical vagus nerve stimulation in patients with drug-refractory gastroparesis. Frontline Gastroenterol. 2017 Oct;8(4):325-330. doi: 10.1136/flgastro-2017-100809. Epub 2017 May 24.</citation>
    <PMID>29067158</PMID>
  </reference>
  <reference>
    <citation>Lerman I, Hauger R, Sorkin L, Proudfoot J, Davis B, Huang A, Lam K, Simon B, Baker DG. Noninvasive Transcutaneous Vagus Nerve Stimulation Decreases Whole Blood Culture-Derived Cytokines and Chemokines: A Randomized, Blinded, Healthy Control Pilot Trial. Neuromodulation. 2016 Apr;19(3):283-90. doi: 10.1111/ner.12398. Epub 2016 Mar 15.</citation>
    <PMID>26990318</PMID>
  </reference>
  <reference>
    <citation>Tarn J, Legg S, Mitchell S, Simon B, Ng WF. The Effects of Noninvasive Vagus Nerve Stimulation on Fatigue and Immune Responses in Patients With Primary Sjögren's Syndrome. Neuromodulation. 2019 Jul;22(5):580-585. doi: 10.1111/ner.12879. Epub 2018 Oct 17.</citation>
    <PMID>30328647</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Jessica Robinson-Papp</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Small intestinal bacterial overgrowth</keyword>
  <keyword>People living with HIV</keyword>
  <keyword>HIV-associated autonomic neuropathy</keyword>
  <keyword>Distal symmetric polyneuropathy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridostigmine Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>Anyone who wishes to access the data. Data will be published.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

